ReviewIJID regions2026
Evaluating the economic burden of dengue in Sri Lanka: A systematic review of costs from 2010 to 2024.
Review in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Severe Dengue in Children: Pathogenesis, Early Recognition, and Evidence-Informed Management.Tropical medicine and infectious disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This systematic literature review aimed to evaluate the direct and indirect costs borne by households and the health care system in managing dengue cases in Sri Lanka. Methods: This review evaluates the economic burden of dengue in Sri Lanka from 2010 to 2024, following the Cochrane Handbook for Systematic Reviews of Interventions and PRISMA guidelines. The databases PubMed, Embase, Cochrane, and the Database of Abstracts of Reviews of Effects (DARE) were searched, with a final selection of eight studies that covered direct, indirect, and vector control costs. Costs were converted to 2024 US dollar (USD) using the Sri Lankan Consumer Price Index. Results: Direct costs ranged from 19 USD per case in southern Sri Lanka to 242 USD nationally, with hospitalization as a major expense. Indirect costs, including lost income from missed workdays, averaged 371 USD per episode, reducing household income by 6.18%. In 2017, the total annual cost of implementing the dengue vaccination strategy was estimated at USD 28.95 million. In comparison, the total cost of a dengue vector control program was USD 400,496, with a cost of USD 2 per person protected over the intervention period (2014-2016). Psychological effects such as post-infectious fatigue, depression, and anxiety were frequently reported. Conclusions: This review highlights dengue's economic burden in Sri Lanka, emphasizing the need for cost-effective interventions and mental health support, alongside disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.